Literature DB >> 11745932

Community-based seroepidemiological survey of HCV infection in Catalonia, Spain.

A Domínguez1, M Bruguera, J Vidal, P Plans, L Salleras.   

Abstract

The objective of this study was to investigate the prevalence of antibodies against the hepatitis C virus (anti-HCV) and the associated risk factors in a representative sample of the population of Catalonia, Spain. Serum samples from 2,142 subjects aged between 5 and 70 years, selected at random from urban and rural habitats, were studied. Multiple logistic regression analysis was carried out to determine variables associated independently with the presence of HCV antibodies. The age and gender standardized prevalence of anti-HCV was 2.5% (95% confidence interval, 1.8-3.2). Prevalence increased significantly with age (P < 0.001), but no other sociodemographic variables were associated with HCV infection. Tattoos (OR: 6.2), blood transfusions (OR: 5.0) intravenous drug use (OR: 4.9) and antecedents of hospitalization (OR: 2.3) were variables associated independently with infection. HCV infection affects mainly elderly people in Spain and spares children and adolescents. This suggests that major exposure to HCV may have occurred many years ago, when infection was more widespread than in recent years. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745932     DOI: 10.1002/jmv.2091

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  14 in total

Review 1.  Aging and liver disease.

Authors:  In Hee Kim; Tatiana Kisseleva; David A Brenner
Journal:  Curr Opin Gastroenterol       Date:  2015-05       Impact factor: 3.287

Review 2.  Transmission of hepatitis C virus infection through tattooing and piercing: a critical review.

Authors:  Rania A Tohme; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2012-01-30       Impact factor: 9.079

3.  Prevalence and risk factors for hepatitis C infection in rural north Vietnam.

Authors:  Van Thi Thuy Nguyen; Mary-Louise McLaws; Gregory J Dore
Journal:  Hepatol Int       Date:  2007-07-19       Impact factor: 6.047

Review 4.  Epidemiology of hepatitis C virus infection.

Authors:  Miriam J Alter
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

Review 5.  Hepatitis C virus infection in the elderly: epidemiology, natural history and management.

Authors:  Francesca Cainelli
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

6.  Labour productivity losses caused by premature death associated with hepatitis C in Spain.

Authors:  Juan Oliva-Moreno; Luz M Peña-Longobardo; Sonia Alonso; Antonio Fernández-Bolaños; María Luisa Gutiérrez; Álvaro Hidalgo-Vega; Elsa de la Fuente; Conrado M Fernández-Rodríguez
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-06       Impact factor: 2.566

Review 7.  Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.

Authors:  Martin Lagging; Rune Wejstål; Gunnar Norkrans; Olle Karlström; Soo Aleman; Ola Weiland; Maria Castedal; Filip Josephson
Journal:  Infect Dis (Lond)       Date:  2015-12-01

8.  Hepatitis C hospitalizations in Spain, 2004-2013: a retrospective epidemiological study.

Authors:  R Boix; R Cano; P Gallego; F Vallejo; R Fernández-Cuenca; I Noguer; A Larrauri
Journal:  BMC Health Serv Res       Date:  2017-07-05       Impact factor: 2.655

Review 9.  Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.

Authors:  Susan J M Hahné; Irene K Veldhuijzen; Lucas Wiessing; Tek-Ang Lim; Mika Salminen; Marita van de Laar
Journal:  BMC Infect Dis       Date:  2013-04-18       Impact factor: 3.090

10.  Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations.

Authors:  Barbara Bertisch; Fabio Giudici; Francesco Negro; Darius Moradpour; Beat Müllhaupt; Alberto Moriggia; Janne Estill; Olivia Keiser
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.